Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 24;5:9248. doi: 10.1038/srep09248

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Macmillan Publishers Limited. All rights reserved

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Phase contrast image (20×) of utNSCs (top) and tdNSCs (bottom) after 6-day incubation with anti-human-IgG, ephrin-B2 or ephrin-B3. (b) utNSCs, RGCH02 and RGPC01 sphere formation assay (**** (p < 0.0001) vs. utNSCs). (c) IP/Western of Ink4a/Arf^(−/−) STeNSCs (lane 1), utNSCs (lanes 2), tdNSC lines RGPC02, RGCH01-RA, RGPC01-RP, and RGPC03-RM (lanes 3–6), utNSCs treated with ephrin-B2 (lane 7) or anti-human-IgG (lane 8). IP with EphB2 antibody, western blot with phospho-tyrosine (top) or EphB2 (bottom). Graphs of neurosphere (d) and tumorsphere (e) number, area and roundness after treatment with anti-human-IgG, ephrin-B2 or ephrin-B3. * (p < 0.05) and **** (p < 0.0001) vs. anti-human-IgG.